Vermillion this week named Sandra Gardiner as its chief financial officer.
Gardiner comes to Vermillion from Bend Research, where she had been CFO since March 2009. Previously she worked as CFO and corporate secretary of Lipid Sciences and held various positions at Cardima, Comac, and Advance Cardiovascular Systems.
She will be responsible for all aspects of financial management at Vermillion, which emerged from Chapter 11 bankruptcy protection in January of this year.
Jonathan Knowles was named this week to the newly created position of chief scientific officer at Caris Life Sciences.
Knowles became vice chairman of Caris at the beginning of this year. Previously he had been president of group research at Roche and the first chairman of the board for the Innovative Medicines Initiative – a public-private partnership between the European Commission and 28 pharmaceutical companies.
Caris said in a statement that in the new position Knowles would be responsible for developing novel assays using the company's Carisome platform as well as "the expansion and globalization of the company's overall scientific and research capabilities."
Danaher executive vice president Thomas Joyce has assumed the role of president at AB Sciex. An employee of Danaher since joining the company as a product manager in 1989, Joyce took over as AB Sciex president this April and is now responsible for the day-to-day operations of the company.
Andy Boorn, formerly president at AB Sciex along with Laura Lauman, has taken over as the company's COO. Lauman has left the company to pursue other opportunities.
Dave Tapolczay was appointed this week non-executive chairman at biomarker discovery and bioinformatics firm Compandia.
CEO of Medical Research Council Technology, Tapolczay previously held positions at GlaxoSmithKline, Millennium Pharmaceuticals, Pharmorphix, and AstraZeneca.